[go: up one dir, main page]

ME02513B - Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije - Google Patents

Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije

Info

Publication number
ME02513B
ME02513B MEP-2016-226A MEP2016226A ME02513B ME 02513 B ME02513 B ME 02513B ME P2016226 A MEP2016226 A ME P2016226A ME 02513 B ME02513 B ME 02513B
Authority
ME
Montenegro
Prior art keywords
compound
deuterium
atom
labeled
disorder
Prior art date
Application number
MEP-2016-226A
Other languages
German (de)
English (en)
French (fr)
Inventor
Morten Jorgensen
Peter Hongaard Andersen
Klaus Gjervig Jensen
Mette Graulund Hvenegaard
Lassina Badolo
Mikkel Fog Jacobsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ME02513B publication Critical patent/ME02513B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (31)

1.Jedinjenje formule Y: u kojoj,R1 - R10 su nezavisno vodonik ili deuterijum, pri čemu su R6-R10 svaki deuterijum, i gde najmanje jedan od R1-R10 obuhvata najmanje oko 50% deuterijuma, ili njegova farmaceutski prihvatljiva adiciona so sa kiselinom.
2.  Jedinjenje prema zahtevu 1, u kojem su R3-R5 svaki vodonik.
3.  Jedinjenje prema zahtevu 1, u kojem su R3-R5 svaki deuterijum.
4.  Jedinjenje prema zahtevu 2, gde je jedinjenje
5.  Jedinjenje prema zahtevu 2, gde je jedinjenje
6.  Jedinjenje prema zahtevu 3, gde je jedinjenje
7.  Jedinjenje prema zahtevu 3, gde je jedinjenje
8.  Jedinjenje prema zahtevu 1, u kojem su R1 i R2 svaki deuterijum.
9.  Jedinjenje prema zahtevu 8, u kojem su R3-R5 svaki deuterijum.
10.  Jedinjenje prema zahtevu 8, u kojem su R3-R5 svaki vodonik.
11.  Jedinjenje prema bilo kom od zahteva 1-10, u kojem najmanje oko 85% jedinjenja ima atom deuterijuma na svakom položaju označenom kao deuterijum, a svaki atom koji nije označen kao deuterijum prisutan je otprilike u svojoj prirodnoj izotopskoj rasprostranjenosti.
12.  Jedinjenje prema bilo kom od zahteva 1-11, u kojem najmanje oko 90% jedinjenja ima atom deuterijuma na svakom položaju označenom kao deuterijum, a svaki atom koji nije označen kao deuterijum prisutan je otprilike u svojoj prirodnoj izotopskoj rasprostranjenosti.
13.  Jedinjenje prema zahtevu 1, gde je jedinjenje hidrogen tartaratna so
14.  Jedinjenje prema zahtevu 13, u kojem jedinjenje postoji u polimorfnom obliku koji ima XRPD difrakcioni obrazac kakav je prikazan na Fig. 18.
15.  Jedinjenje prema zahtevu 13, u kojem najmanje oko 85% jedinjenja ima atom deuterijuma na svakom položaju označenom kao deuterijum, a svaki atom koji nije označen kao deuterijum prisutan je otprilike u svojoj prirodnoj izotopskoj rasprostranjenosti.
16.  Farmaceutska kompozicija koja obuhvata jedinjenje prema bilo kom od zahteva 1 do 15 i jedan ili više farmaceutski prihvatljivih nosača, razblaživača ili ekscipijenasa.
17.  Farmaceutska kompozicija prema zahtevu 16, gde je jedinjenje hidrogen tartaratna so
18.  Kompozicija prema zahtevima 16 ili 17, u kojoj nosač obuhvata hidroksipropil-β-ciklodekstrin u vodi, i u kojoj najmanje oko 85% jedinjenja ima atom deuterijuma na svakom položaju označenom kao deuterijum, a svaki atom koji nije označen kao deuterijum prisutan je otprilike u svojoj prirodnoj izotopskoj rasprostranjenosti.
19.  Upotreba jedinjenja prema bilo kom od zahteva 1-15, ili kompozicija prema bilo kom od zahteva 16-18 za proizvodnju leka za tretiranje psihoze, ostalih bolesti koje uključuju psihotične simptome, psihotičnih poremećaja ili bolesti koje su prisutne sa psihotičnim simptomima.
20.  Upotreba prema zahtevu 19, pri čemu je psihoza ili bolest koja uključuje psihotične simptome šizofrenija, šizofreniformni poremećaj, šizoafektivni poremećaj, deluzioni poremećaj, kratkotrajni psihotični poremećaj, podeljeni psihotični poremećaj, bipolarni poremećaj ili manija u bipolarnom poremećaju.
21.  Upotreba prema bilo kom od zahteva 19-20, koja dalje obuhvata jedinjenje odabrano iz grupe koja se sastoji od sertindola, olanzapina, risperidona, kvetiapina, aripiprazola, haloperidola, klozapina, ziprasidona i osanetanta.
22.  Upotreba prema bilo kom od zahteva 19-20, gde je psihoza ili bolest koja uključuje psihotične simptome šizofrenija.
23.  Upotreba prema bilo kom od zahteva 19-20, gde je psihoza ili bolest koja uključuje psihotične simptome šizofrenija, pri čemu farmaceutska kompozicija obuhvata efektivnu količinu hidrogen tartaratne soli i hidroksipropil-β-ciklodekstrin u vodi, i gde najmanje oko 85% (IV) ima atom deuterijuma na svakom položaju označenom kao deuterijum, a svaki atom koji nije označen kao deuterijum prisutan je otprilike u svojoj prirodnoj izotopskoj rasprostranjenosti.
24.  Jedinjenje formule
25.  Postupak za pripremanje jedinjenja koji obuhvata tretiranje jedinjenja (XIV) sa [(S)-BINAP]Rh(I)BF4.
26.  Postupak prema zahtevu 25, u kojem se [(S)-BINAP]Rh(I)BF4 primenjuje u katalitičkoj količini.
27.  Postupak za pripremanje jedinjenja (XIV) koji obuhvata a) tretiranje bis(pinakolato) diboronom, i b) tretiranje 2-bromo-5-hlorobenzaldehidom.
28.  Postupak prema zahtevu 27, u kojem tretiranje bis(pinakolato) diboronom dalje obuhvata dodavanje Pd(II).
29.  Postupak prema zahtevu 28, u kojem tretiranje 2-bromo-5-hlorobenzaldehidom dalje obuhvata dodavanje Pd(0).
30.  Postupak za pripremanje jedinjenja (1R,3S)-(IV) tartarat, koji obuhvata tretiranje racemskog trans-1-(6-hloro-3-fenil(d5)-indan-1-il)-1(d3), 2, 2-trimetil-piperazina L-(+)-vinskom kiselinom.
31.  Postupak prema zahtevu 30, u kojem se racemski trans-1-(6-hloro-3-fenil(d5)-indan-1-il)-1(d3), 2, 2-trimetil-piperazin generiše iz njegove odgovarajuće sukcinatne soli.
MEP-2016-226A 2011-06-20 2012-06-19 Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije ME02513B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21
EP12748046.5A EP2720989B1 (en) 2011-06-20 2012-06-19 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
PCT/IB2012/001386 WO2012176066A1 (en) 2011-06-20 2012-06-19 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
ME02513B true ME02513B (me) 2017-02-20

Family

ID=46682855

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2016-226A ME02513B (me) 2011-06-20 2012-06-19 Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
MEP-2019-93A ME03375B (me) 2011-06-20 2012-06-19 Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2019-93A ME03375B (me) 2011-06-20 2012-06-19 Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije

Country Status (41)

Country Link
US (8) US8575174B2 (me)
EP (4) EP3135656B1 (me)
JP (1) JP5668177B2 (me)
KR (2) KR101879474B1 (me)
CN (1) CN103649019B (me)
AP (1) AP3310A (me)
AR (1) AR086987A1 (me)
AU (1) AU2012273657B2 (me)
BR (1) BR112013031702B1 (me)
CA (1) CA2837820C (me)
CL (1) CL2013003646A1 (me)
CO (1) CO6821965A2 (me)
CR (1) CR20130654A (me)
CY (2) CY1118158T1 (me)
DK (2) DK2720989T3 (me)
DO (1) DOP2013000305A (me)
EA (1) EA024651B1 (me)
EC (1) ECSP14013155A (me)
ES (3) ES2719145T3 (me)
GE (1) GEP201706655B (me)
GT (1) GT201300304A (me)
HK (1) HK1197228A1 (me)
HR (2) HRP20161348T1 (me)
HU (2) HUE030883T2 (me)
IL (1) IL229640B (me)
JO (1) JO3128B1 (me)
LT (2) LT2720989T (me)
MA (1) MA35268B1 (me)
MD (1) MD4538C1 (me)
ME (2) ME02513B (me)
MX (1) MX339552B (me)
MY (1) MY196998A (me)
PE (2) PE20141113A1 (me)
PH (1) PH12013502598A1 (me)
PL (2) PL3135656T3 (me)
PT (2) PT2720989T (me)
RS (2) RS58546B1 (me)
SI (2) SI2720989T1 (me)
SM (2) SMT201900179T1 (me)
TW (3) TWI627956B (me)
WO (1) WO2012176066A1 (me)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101879474B1 (ko) * 2011-06-20 2018-07-17 하. 룬드벡 아크티에셀스카브 정신 분열증의 치료를 위한 중수소화 1-피페라지노-3-페닐 인단
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
WO2019049918A1 (en) 2017-09-07 2019-03-14 Otsuka Pharmaceutical Co., Ltd. INDUSTRIAL PROCESS FOR MONOALKYLATION OF PIPERIDINE NITROGEN IN PIPERIDINE DERIVATIVES WITH DEUTERATED ALKYL
JP7442538B2 (ja) 2018-10-29 2024-03-04 ハー・ルンドベック・アクチエゼルスカベット 非晶性の式（ｉ）の化合物及び非晶性の式（ｉ）の化合物塩
CN113056457A (zh) 2018-12-03 2021-06-29 H.隆德贝克有限公司 4-((1R,3S)-6-氯-3-苯基-2,3-二氢-1H-茚-1-基)-1,2,2-三甲基哌嗪和4-((1R,3S)-6-氯-3-(苯基-d5)-2,3-二氢-1H-茚-1-基)-2,2-二甲基-1-(甲基-d3)哌嗪的前药
WO2020132461A1 (en) * 2018-12-21 2020-06-25 Concert Pharmaceuticals, Inc. Deuterated forms and derivatives of volinanserin
KR20210139317A (ko) * 2019-03-13 2021-11-22 오츠카 세이야쿠 가부시키가이샤 2급 아민을 함유하는 화합물의 아민 부분에 중수소 저급 알킬을 도입하는 방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
ATE60571T1 (de) 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69535592T2 (de) * 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AR045279A1 (es) * 2003-08-18 2005-10-19 Lundbeck & Co As H Trans-1-(6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina
CA2536144C (en) 2003-08-18 2010-09-14 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
NZ552411A (en) 2004-06-08 2010-04-30 Nsab Af Neurosearch Sweden Ab New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
RU2366654C2 (ru) 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
JP2008530039A (ja) 2005-02-16 2008-08-07 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
AU2006275595B2 (en) 2005-07-29 2012-08-16 Concert Pharmaceuticals Inc. Novel benzo [d] [1,3]-dioxol derivatives
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
CA2631581C (en) 2005-12-01 2011-05-03 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
WO2008086158A1 (en) 2007-01-04 2008-07-17 Smithkline Beecham Corporation Benzodihydroquinazoline as pi3 kinase inhibitors
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP1997479A1 (en) 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
PL2003120T3 (pl) 2007-06-12 2010-04-30 Concert Pharmaceuticals Inc Pochodne azapeptydu jako inhibitory proteazy HIV
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
CA2722374A1 (en) 2008-05-07 2009-11-12 H. Lundbeck A/S Method for treating cognitive deficits
US20110178094A1 (en) 2008-10-03 2011-07-21 H. Lundbeck A/S Oral Formulation
KR20110110097A (ko) 2008-10-28 2011-10-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 수난용성 성분을 위한 메조포러스 물질 부형제
US20120071554A1 (en) 2008-10-28 2012-03-22 Liu Julie F Deuterated 2-propylpentanoic acid compounds
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
US8557994B2 (en) 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
DK2639216T3 (en) 2010-11-09 2018-09-24 Kaneka Corp Halogenated Indones and Methods for Preparation of Optically Active Indanones or Optically Active Indanols Using These
EP2661427A1 (en) 2011-01-07 2013-11-13 H. Lundbeck A/S Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine
EP2693876B1 (en) 2011-04-08 2020-01-15 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
KR101879474B1 (ko) 2011-06-20 2018-07-17 하. 룬드벡 아크티에셀스카브 정신 분열증의 치료를 위한 중수소화 1-피페라지노-3-페닐 인단
US9487500B2 (en) 2012-10-04 2016-11-08 Inhibikase Therapeutics, Inc. Compounds and compositions thereof
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma

Also Published As

Publication number Publication date
ES2939477T3 (es) 2023-04-24
HRP20161348T1 (hr) 2016-12-02
HRP20190593T1 (hr) 2019-05-17
EP2720989A1 (en) 2014-04-23
US9012453B2 (en) 2015-04-21
PT2720989T (pt) 2016-11-07
US9617231B2 (en) 2017-04-11
DOP2013000305A (es) 2014-02-28
KR101879474B1 (ko) 2018-07-17
US20200131143A1 (en) 2020-04-30
PT3135656T (pt) 2019-05-03
CN103649019B (zh) 2015-09-16
CR20130654A (es) 2014-03-24
MY196998A (en) 2023-05-17
AR086987A1 (es) 2014-02-05
TWI659741B (zh) 2019-05-21
TWI627956B (zh) 2018-07-01
US20150307458A1 (en) 2015-10-29
BR112013031702A2 (pt) 2016-12-13
US20160068497A1 (en) 2016-03-10
CL2013003646A1 (es) 2014-07-04
GEP201706655B (en) 2017-04-25
MX339552B (es) 2016-05-31
DK3135656T3 (en) 2019-04-23
US20130281436A1 (en) 2013-10-24
US20120322811A1 (en) 2012-12-20
TW201311248A (zh) 2013-03-16
WO2012176066A1 (en) 2012-12-27
ES2719145T3 (es) 2019-07-08
US20220119362A1 (en) 2022-04-21
KR101939546B1 (ko) 2019-01-16
NZ618222A (en) 2015-03-27
US12116355B2 (en) 2024-10-15
IL229640A0 (en) 2014-01-30
LT3135656T (lt) 2019-04-25
TW201722895A (zh) 2017-07-01
EP2720989B1 (en) 2016-08-10
ES2601213T3 (es) 2017-02-14
AU2012273657A1 (en) 2013-12-12
SI2720989T1 (sl) 2016-11-30
EP3508468B1 (en) 2023-01-18
EP3508468A1 (en) 2019-07-10
KR20140041567A (ko) 2014-04-04
AP3310A (en) 2015-06-30
US11059798B2 (en) 2021-07-13
MD20140004A2 (en) 2014-05-31
SMT201900179T1 (it) 2019-05-10
PL3135656T3 (pl) 2019-07-31
LT2720989T (lt) 2016-11-25
SI3135656T1 (sl) 2019-05-31
CY1118158T1 (el) 2017-06-28
JO3128B1 (ar) 2017-09-20
TW201902481A (zh) 2019-01-16
US10501427B2 (en) 2019-12-10
TWI614234B (zh) 2018-02-11
ME03375B (me) 2020-01-20
MA35268B1 (fr) 2014-07-03
CY1121514T1 (el) 2020-05-29
GT201300304A (es) 2015-01-16
JP5668177B2 (ja) 2015-02-12
KR20180075717A (ko) 2018-07-04
MD4538B1 (ro) 2017-12-31
CN103649019A (zh) 2014-03-19
CO6821965A2 (es) 2013-12-31
EP3135656A1 (en) 2017-03-01
US20170158650A1 (en) 2017-06-08
RS58546B1 (sr) 2019-05-31
SMT201600383B (it) 2017-01-10
DK2720989T3 (en) 2016-11-28
HUE030883T2 (en) 2017-06-28
EA201490045A1 (ru) 2014-07-30
RS55304B1 (sr) 2017-03-31
PE20141113A1 (es) 2014-09-25
US9216961B2 (en) 2015-12-22
AP2013007338A0 (en) 2013-12-31
EP3135656B1 (en) 2019-02-27
HK1197228A1 (zh) 2015-01-09
IL229640B (en) 2018-02-28
ECSP14013155A (es) 2014-02-28
AU2012273657B2 (en) 2016-07-21
MX2013014849A (es) 2014-03-31
PE20150928A1 (es) 2015-06-26
MD4538C1 (ro) 2018-07-31
HUE044043T2 (hu) 2019-09-30
BR112013031702B1 (pt) 2021-11-03
CA2837820A1 (en) 2012-12-27
EA024651B1 (ru) 2016-10-31
US10118907B2 (en) 2018-11-06
JP2014520140A (ja) 2014-08-21
US20190031631A1 (en) 2019-01-31
PL2720989T3 (pl) 2017-05-31
EP4215512A1 (en) 2023-07-26
CA2837820C (en) 2019-02-19
US8575174B2 (en) 2013-11-05
PH12013502598A1 (en) 2014-02-10

Similar Documents

Publication Publication Date Title
ME02513B (me) Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
JP2014520140A5 (me)
MY165906A (en) Phenothiazine diaminium salts and their use
BR112015012425A2 (pt) composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
DOP2013000194A (es) Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos
CN101175714A (zh) 经不对称氢化制备手性β氨基酸衍生物的方法
ME02452B (me) Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti
MX374638B (es) Los acidos sorbico y benzoico y sus derivados aumentan la actividad de un neurofarmaco.
ME02861B (me) Postupak za pripremu treprostinila i njegovih derivata
MX351467B (es) Nuevos derivados de fosfato de isoquinolinilcarbonilfenil indolizinilo o fosfato de isoquinolinilcarbonilfenil pirrolilo sustituidos, metódo para prepararlos y composiciones farmacéuticas que lo contienen.
MX2015014387A (es) Quinazolinas y azaquinazolinas como inhibidores duales de vias ras/raf/mek/erk y pi3k/akt/pten/mtor.
KR102314248B1 (ko) 정신분열병의 음성 증상을 치료하기 위한 트랜스-4-[2-[4-(2,3-디클로로페닐)-피페라진-1-일]-에틸]-n,n-디메틸카바모일-사이클로헥실아민
BR112015012909A2 (pt) compostos de ácido borônico de triazol substituído
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
UY34239A (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
CO6680653A2 (es) Fabricación del inhibidor inter-alfa(iaip) a partir de plasma
CA3025586A1 (en) Pde9 inhibitors for treatment of peripheral diseases
HRP20140336T1 (hr) Inhibitori glicin transportera-1
CO6220957A2 (es) 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid
ECSP045373A (es) Sales de tolterodina
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
HRP20170075T1 (hr) Spoj benzotiazolona